Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News OmniAb Inc OABI

Healthcare Biotechnology
OmniAb, Inc. licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to identify optimal antibodies and other target-binding proteins for its partners’ drug development efforts. Central to the OmniAb platform... see more

Recent & Breaking News (NDAQ:OABI)

OmniAb Announces Two New Appointments to its Board of Directors

Business Wire 7 days ago

OmniAb to Report First Quarter 2025 Financial Results on May 8

Business Wire April 14, 2025

OmniAb Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

Business Wire March 18, 2025

OmniAb to Report Fourth Quarter 2024 Financial Results on March 18

Business Wire February 24, 2025

OmniAb to Participate in Two Investor Conferences in March

Business Wire February 3, 2025

Kuehn Law Encourages Investors of OmniAb, Inc. to Contact Law Firm

PR Newswire January 31, 2025

Kuehn Law Encourages Investors of OmniAb, Inc. to Contact Law Firm

Newsfile January 7, 2025

OmniAb Technologies Featured in Two Presentations at the 2024 Antibody Engineering & Therapeutics Conference

Business Wire December 16, 2024

OmniAb Reports Third Quarter 2024 Financial Results and Business Highlights

Business Wire November 12, 2024

OmniAb to Participate in Two Investor Conferences in November

Business Wire October 30, 2024

OmniAb to Report Third Quarter 2024 Financial Results on November 12

Business Wire October 22, 2024

OmniAb to Participate in Two Investor Conferences in September

Business Wire August 26, 2024

OmniAb Reports Second Quarter 2024 Financial Results and Business Highlights

Business Wire August 8, 2024

OmniAb to Report Second Quarter 2024 Financial Results on August 8

Business Wire July 25, 2024

OmniAb Announces Publication of Scientific Paper on Heavy Chain-Only Single-Domain Antibody Chicken Platform in the Journal of Immunology

Business Wire June 3, 2024

OmniAb to Participate in the Jefferies Global Healthcare Conference

Business Wire May 20, 2024

OmniAb Presents High-Throughput Single B-cell Screening xPloration® Data at the 20th Annual PEGS Boston Summit

Business Wire May 15, 2024

OmniAb Reports First Quarter 2024 Financial Results and Business Highlights

Business Wire May 9, 2024

OmniAb to Participate in Five Investor Conferences in May

Business Wire May 1, 2024

OmniAb to Report First Quarter 2024 Financial Results on May 9

Business Wire April 22, 2024